Amgen, GSK Pediatric Oncology Studies Could Change Based on Advisory Committee Comments
This article was originally published in The Pink Sheet Daily
FDA’s pediatric oncology subcommittee will consider the best study designs to isolate pediatric clinical benefit in Amgen’s blinatumomab and whether pediatric use can be extrapolated from adult data in GSK’s trametinib.
You may also be interested in...
Phase I/II data for Glaxo’s BRAF/MEK combination of dabrafenib and trametinib, both pending FDA approval as single agents, suggest compelling efficacy. The combination may see off-label use if the drugs are approved as monotherapies, though payment could be a big hurdle.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.